Varenicline Is More Effective in Attenuating Weight Gain Than Nicotine Patch 12 Months After the End of Smoking Cessation Therapy: An Observational Study in Japan

2014 ◽  
Vol 16 (7) ◽  
pp. 1026-1029 ◽  
Author(s):  
C. Taniguchi ◽  
H. Tanaka ◽  
N. Nakamura ◽  
H. Saka ◽  
I. Oze ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Observational Study ◽  
Nicotine Patch ◽  
Smoking Cessation Therapy

Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: a Pilot Randomized Controlled Trial

2021 ◽  
Author(s):  
Luba Yammine ◽  
Charles E Green ◽  
Thomas R Kosten ◽  
Constanza de Dios ◽  
Robert Suchting ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Body Weight ◽  
Weight Gain ◽  
Extended Release ◽  
Nicotine Patch ◽  
Withdrawal Symptoms ◽  
Secondary Outcome ◽  
Smoking Abstinence ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Abstract Introduction Approved pharmacological treatments for smoking cessation are modestly effective, underscoring the need for improved pharmacotherapies. Glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the rewarding effects of nicotine in preclinical studies. We examined the efficacy of extended-release exenatide, a GLP-1R agonist, combined with nicotine replacement therapy (NRT, patch) for smoking cessation, craving and withdrawal symptoms, with post-cessation body weight as secondary outcome. Methods Eighty-four prediabetic and/or overweight smokers were randomized (1:1) to once-weekly placebo or exenatide, 2 mg, subcutaneously. All participants received NRT (21 mg) and brief smoking cessation counseling. Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal and post-cessation body weight were assessed following 6 weeks of treatment. A Bayesian approach for analyzing generalized linear models yielded posterior probabilities (PP) to quantify the evidence favoring hypothesized effects of treatment on the study outcomes. Results Exenatide increased the risk for smoking abstinence compared to placebo (46.3% and 26.8%, respectively), (RR = 1.70; 95% credible interval = [0.96, 3.27]; PP = 96.5%). Exenatide reduced end-of-treatment craving in the overall sample and withdrawal among abstainers. Post-cessation body weight was 5.6 pounds lower in the exenatide group compared to placebo (PP=97.4%). Adverse events were reported in 9.5% and 2.3% of participants in the exenatide and placebo groups, respectively. Conclusions Exenatide, in combination with the NRT improved smoking abstinence, reduced craving and withdrawal symptoms, and decreased weight gain among abstainers. Findings suggest that the GLP-1R agonist strategy is worthy of further research in larger, longer duration studies. Implications Despite considerable progress in tobacco control, cigarette smoking remains the leading cause of preventable disease, disability, and death. In this pilot study, we showed that extended-release exenatide, a glucagon-like peptide-1 receptor agonist, added to the nicotine patch, improved abstinence and mitigated post-cessation body weight gain compared to patch alone. Further research is needed to confirm these initial positive results.

scholarly journals Determining the effects of exercise after smoking cessation therapy completion on continuous abstinence from smoking: A study protocol

2019 ◽  
Author(s):  
Yuka Ozaki ◽  
Maki Komiyama ◽  
Kenji Ueshima ◽  
Hiroyasu Iso ◽  
Satoko Sakata ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Intervention Group ◽  
Abstinence Rate ◽  
Psychological State ◽  
Control Group ◽  
Standard Instruction ◽  
Continuous Abstinence ◽  
Therapy Completion ◽  
Smoking Cessation Therapy

Abstract Background: Over the past few years, the rate of success for smoking cessation has improved markedly owing to the widespread availability of drug therapy; however, the quit rate 1 year after the beginning of therapy remains low at approximately 50%. Previous studies have demonstrated that exercise can relieve mental stress during continuous abstinence from smoking and curb the resumption of smoking. Nonetheless, very few studies have examined the effects of exercise therapy combined with continuous abstinence from smoking; those studies involved only a handful of patients. Thus, this study will examine continuous abstinence from smoking coupled with instructions on specific forms of exercise in individuals who are attempting to quit smoking but do not exercise. We aimed to determine the effects of implementing an intervention in the form of exercise instruction after smoking cessation therapy completion on continuous abstinence from smoking. If this study finds that exercise instruction increases the continuous abstinence rate, widespread implementation of the intervention is expected to reduce public smoking rate, promote health, reduce medical expenses, and greatly benefit the public. Methods: We will enroll patients visiting a smoking cessation clinic (over a 3-month period) who have abstained from smoking in the second month after their initial visit as potential subjects and patients aged 20–75 years who do not exercise and who consent to participation in this study as subjects. We aim to enroll 300 patients. Subjects will be randomly assigned to one of the following two groups: an intervention group actively given exercise instruction in addition to the standard instruction and a control group given the standard instruction. The status of the two groups will be assessed after 9 months. The intervention group will receive instruction on exercises that can be incorporated into their daily lives. Additionally, members of this group will be lent a pedometer and encouraged to record their daily step count, level of activity, and weight during follow-up. The control group will be followed during the standard smoking cessation support program. The primary endpoint will be the continuous abstinence rate, and secondary endpoints will be weight, blood pressure, exhaled carbon monoxide concentration, psychological state, and blood test results. These indices will be compared between the intervention and control groups; the study will be conducted over a 9-month period. Discussion: By examining the effects of exercise instruction after 12-weeks smoking cessation therapy completion (covered by the National Health Insurance), this study will yield quality information for the development of protocols to improve the continuous abstinence rate and inhibit weight gain after smoking cessation therapy. Trial registration: The study is registered at UMIN Clinical Trials Registry (UMIN000014615). Registered on 1st October, 2014. Keywords: Smoking cessation, exercise, weight gain, obesity

scholarly journals Triple Smoking Cessation Therapy with Varenicline, Nicotine Patch and Nicotine Lozenge: A Pilot Study to Assess Tolerability, Satisfaction and End-of-Treatment Quit Rates

2017 ◽  
Vol 13 (3) ◽  
pp. 145-153
Author(s):  
Kristin M. Berg ◽  
Douglas E. Jorenby ◽  
Timothy B. Baker ◽  
Michael C. Fiore
Keyword(s):  
Observational Study ◽  
Triple Therapy ◽  
Additional Data ◽  
Nicotine Patch ◽  
Stop Smoking ◽  
End Of Treatment ◽  
Nicotine Lozenge ◽  
Satisfaction Rates ◽  
Medication Changes ◽  
Smoking Cessation Therapy

Introduction: The majority of attempts to stop smoking end in failure. One way to improve success may be to explore different combinations of existing cessation medications.Aims: This observational study examined ‘triple therapy’ (varenicline + nicotine patch + nicotine lozenge) in 36 smokers trying to quit.Methods: A 12-week, observational study exploring tolerability, via adverse events (AEs) elicited at each of nine phone assessments. Secondary outcomes included satisfaction rates, medication changes and self-reported quit rates at week 12.Results: Thirty five of thirty six participants reported at least one AE. Insomnia (75%), abnormal dreams (72%) and nausea (64%) were most common. Most were mild to moderate. No deaths, hospitalisations, cardiovascular events or suicidality were reported. Six participants (17%) decreased the dose of at least one medication, 5 (14%) decreased the dose then discontinued at least one medication and 13 (36%) discontinued at least one medication without trying a lesser dose. Participants were highly satisfied with their medications, and 58% reported quitting at 12 weeks, with 38% reporting prolonged abstinence.Conclusions: Despite high rates of AEs and medication changes, high rates of satisfaction and self-reported quitting, with no serious AEs, were observed with triple therapy. Additional data on tolerability and efficacy are needed.Trial Registration:Clinicaltrials.gov number NCT02681510.

scholarly journals Combination Lorcaserin and Nicotine Patch for Smoking Cessation Without Weight Gain

2019 ◽  
Vol 22 (9) ◽  
pp. 1627-1631 ◽  
Author(s):  
Jed E Rose ◽  
James M Davis
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Weight Change ◽  
Nicotine Patch ◽  
Strong Association ◽  
Smoking Abstinence ◽  
Clinical Trial Registration ◽  
Smoking Cessation Treatment ◽  
Quit Smoking ◽  
The Impact

Abstract Introduction This study explored the efficacy of combination lorcaserin and nicotine patch for smoking cessation treatment and prevention of postsmoking cessation weight gain. Methods We conducted a trial in which 61 adult daily smokers were asked to quit smoking using a combination of lorcaserin and nicotine patch. During the first 2 weeks of treatment prior to the quit day, participants were randomized to receive either lorcaserin (10 mg twice daily) plus nicotine patch (21 mg) or placebo plus nicotine patch (21 mg). Following this 2-week period, participants received both medications for 12 weeks. Outcomes included 4-week continuous smoking abstinence at the end of treatment (weeks 7–10 postquit attempt), weight change, ad libitum smoking, withdrawal symptoms, and ratings of cigarette reward. Results Biochemically confirmed continuous smoking abstinence from 7 to 10 weeks postquit attempt was 31.1% (90% confidence interval, 21.4%–40.8%). Participants who quit smoking showed no weight gain; in fact, mean weight change was minus 0.16 kg (SD = 3.27) over the study period. There was an unexpected but strong association (p = .006) between a decrease in sensory enjoyment of smoking and successful quit outcome on this regimen. During the prequit randomization period, lorcaserin versus placebo reduced the impact of smoking to relieve craving for cigarettes as well as the sensory enjoyment of smoking (p = .005). Adherence and tolerability to lorcaserin and nicotine patch was good. Conclusions The combination of lorcaserin and nicotine patch was well tolerated, associated with a relatively high smoking abstinence rate, and effectively prevented weight gain associated with quitting smoking. Implications This report provides an important contribution to the literature because it details evidence of a medication combination—lorcaserin and nicotine—that is effective for smoking cessation and for ameliorating weight gain associated with smoking cessation. For many smokers, postcessation weight gain is a major obstacle to quitting, and this medication combination provides a suitable treatment option for these smokers. Clinical Trial Registration NCT02906644

scholarly journals Analysis of Factors That Determine Weight Gain during Smoking Cessation Therapy

PLoS ONE ◽  
2013 ◽  
Vol 8 (8) ◽  
pp. e72010 ◽  
Author(s):  
Maki Komiyama ◽  
Hiromichi Wada ◽  
Shuichi Ura ◽  
Hajime Yamakage ◽  
Noriko Satoh-Asahara ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Smoking Cessation Therapy

scholarly journals Effect of nicotine patch on energy intake and weight gain in postmenopausal women during smoking cessation

2013 ◽  
Vol 14 (4) ◽  
pp. 420-423 ◽  
Author(s):  
Alicia M. Allen ◽  
Alison Kleppinger ◽  
Harry Lando ◽  
Cheryl Oncken
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Postmenopausal Women ◽  
Energy Intake ◽  
Nicotine Patch

Factors Associated With Weight Gain After Smoking Cessation Therapy in Japan

2013 ◽  
Vol 62 (6) ◽  
pp. 414-421 ◽  
Author(s):  
Chie Taniguchi ◽  
Hideo Tanaka ◽  
Isao Oze ◽  
Hidemi Ito ◽  
Hideo Saka ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Weight Gain ◽  
Factors Associated ◽  
Smoking Cessation Therapy

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

Addiction ◽  
2009 ◽  
Vol 104 (2) ◽  
pp. 266-276 ◽  
Author(s):  
Nancy A. Rigotti ◽  
David Gonzales ◽  
Lowell C. Dale ◽  
Daniel Lawrence ◽  
Yuchiao Chang
Keyword(s):  
Randomized Controlled Trial ◽  
Smoking Cessation ◽  
Weight Gain ◽  
Nicotine Patch ◽  
Controlled Trial ◽  
Randomized Controlled

Smoking cessation in pregnancy: An observational study

2015 ◽  
Vol 5 (2) ◽  
pp. 43-48
Author(s):  
Pauline Kent ◽  
Mette Jensen ◽  
Rachel Reilly ◽  
Amy McGowan ◽  
Leanne Dineen ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Observational Study ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document